糖原合成酶激酶3 (GSK-3)抑制剂作为治疗乳腺癌和卵巢癌的新先导

Title:Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer

Volume: 22 Issue: 13

关键词: 糖原合酶激酶-3，乳腺癌，卵巢癌，肿瘤，细胞周期，增殖

摘要: A serine/threonine-protein kinase, recognized as Glycogen Synthase Kinase-3 (GSK-3), is documented as a regulator of assorted cellular roles. GSK-3 activates by phosphorylation and thereby controls the action of many physiological, messenger, and membrane-bound structures. GSK-3α and GSK-3β are two vastly homologous forms of GSK-3 in mammals. Recent information has recommended that GSK-3β is a constructive controller of cancer cell proliferation and a promising key target against cancer cells. GSK-3 is overexpressed in various tumor types, including ovarian tumors. In human breast carcinoma, it has been revealed that the overexpression of GSK-3β was linked with breast cancer patients. The inhibition of GSK-3 or inhibitors of GSK-3 is a promising therapeutic tactic to overcome breast and ovarian cancer. This article features an important aspect of inhibitors of Glycogen Synthase Kinase-3 as a new lead for treating breast and ovarian Cancer.

Cite this article as:

Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer, Current Drug Targets 2021; 22 (13) . https://dx.doi.org/10.2174/1389450122666210203183351